ClinicalTrials.govpublic full text
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs
ankylosing spondylitis, biologic therapies, asas, asasbio, etoricoxib, nsaids, cox-2 inhibitor, arcoxia 90 mg, basdai bath ankylosing spondylitis disease activity index, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 868927
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.